Retatrutide and High Blood Pressure: Trial Data

Retatrutide is an investigational triple receptor agonist being studied in clinical trials for obesity and related metabolic conditions, including its potential effects on blood pressure. It has no marketing authorisation in the UK or elsewhere and can only be accessed within an authorised clinical trial. Phase 2 trial data have reported changes in systolic blood pressure among participants, but these are preliminary findings. This article summarises what the published trial data show, who was studied, and the risks of seeking retatrutide outside a regulated trial setting.

What is retatrutide and what is its current UK regulatory status?

Retatrutide has no UK marketing authorisation and can only be supplied within an authorised clinical trial. It is an investigational triple GLP-1, GIP and glucagon receptor agonist; no MHRA approval date has been given.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be supplied only within an authorised clinical trial.^[1] It is an investigational medicine being studied for the management of obesity and related metabolic conditions. Unlike licensed weight-management treatments such as semaglutide (Wegovy) or tirzepatide (Mounjaro), retatrutide has not been evaluated by the MHRA for routine clinical use, and no approval date can be given. Because it is unlicensed, it cannot lawfully be advertised or promoted in the UK, in line with MHRA guidance on unlicensed medicines.^[16]

Pharmacologically, retatrutide is a triple receptor agonist that acts simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors.^[8][9] This triple mechanism distinguishes it from currently licensed dual or single agonists. As of the date of this review, no head-to-head trials comparing retatrutide directly with licensed medicines have been identified in the published literature; any comparison of figures across separate studies would not be scientifically valid.

Because retatrutide is investigational, any product sold online under this name is not a licensed medicine and may be falsified or unsafe. People who are interested in licensed options for weight management or blood pressure control are encouraged to speak with their GP, who can discuss what is currently available on the NHS or through regulated private pathways.

What have clinical trials reported about retatrutide and blood pressure?

Phase 2 trial data published in 2023 reported reductions in systolic blood pressure at various doses, but these are preliminary findings. Full Phase 3 data and regulatory review are still in progress, so no firm conclusions about cardiovascular benefit or risk can yet be drawn.

Phase 2 trial data published in the New England Journal of Medicine in 2023 reported reductions in systolic blood pressure among participants receiving retatrutide, with findings varying by dose and duration.^[8][9] These results were observed in a controlled trial setting and should be understood as preliminary research findings rather than established clinical outcomes.

Some Phase 3 data have since become available, including readouts from the TRANSCEND and TRIUMPH programmes. These have reported continued weight reduction and associated metabolic changes, but full peer-reviewed publications and regulatory submissions are still in progress. Until the complete Phase 3 dataset has been reviewed by regulators, no conclusions about the net cardiovascular benefit or risk of retatrutide should be drawn from interim or topline results alone.

The mechanism by which retatrutide may influence blood pressure is not fully understood. Weight reduction is associated with improvements in blood pressure in people with obesity, and this is likely to contribute to any observed effect.^[17][18] Whether direct vascular or metabolic effects of glucagon receptor agonism play an additional role in humans remains a hypothesis that has not been confirmed by published human mechanistic studies.

The trial data also reported increases in heart rate in some participants, which is a recognised pharmacological effect associated with glucagon receptor agonism.^[8][9] The clinical significance of this finding, particularly in people with pre-existing cardiovascular conditions, remains under investigation and is one of the questions the Phase 3 programme is designed to address.

Who took part in the trials and how does that affect the findings?

Phase 2 trials enrolled carefully selected adults with obesity or overweight, excluding those with significant cardiovascular disease, renal impairment or pregnancy. The blood pressure findings cannot be generalised to broader or more complex patient populations.

The Phase 2 retatrutide trials enrolled adults with obesity or overweight and at least one weight-related comorbidity, but the populations studied were carefully selected according to strict inclusion and exclusion criteria.^[8][9] Participants who were pregnant, breastfeeding or planning a pregnancy were excluded, and contraception requirements applied to those of childbearing potential during participation.^[8][9] This means the safety and efficacy data, including any blood pressure findings, cannot be generalised to these groups.

People with certain cardiovascular conditions, significant renal impairment or other serious comorbidities were also excluded or under-represented in the Phase 2 cohort. This is clinically relevant when considering the blood pressure findings: the participants who showed reductions in systolic blood pressure were not necessarily representative of the broader population of people living with hypertension, particularly those with complex or treatment-resistant high blood pressure.

The trial duration in Phase 2 was also limited, meaning that longer-term effects on blood pressure, whether sustained, attenuated or reversed over time, were not captured. Some Phase 3 data from the TRANSCEND and TRIUMPH programmes have now reported, providing information from larger and more varied populations over longer follow-up periods. However, the full programme has not yet completed regulatory review, and it would be premature to draw firm conclusions about the durability or clinical significance of the blood pressure signals observed in Phase 2 until that process is complete.

What are the risks of obtaining retatrutide outside a clinical trial?

Any substance sold as retatrutide outside an authorised trial is unlicensed and may be falsified, incorrectly dosed or contaminated. Using it without medical supervision is particularly dangerous for people with high blood pressure who require regular monitoring and medication adjustment.

Obtaining retatrutide outside an authorised clinical trial carries serious risks, because no version of this medicine has been approved for manufacture, sale or supply by the MHRA or any other regulatory authority. Any substance sold online or through unregulated channels as retatrutide is not a licensed product and may contain incorrect doses, harmful contaminants or entirely different compounds. The MHRA has warned that falsified injectable medicines pose significant dangers, including severe infection, allergic reactions and unpredictable pharmacological effects.^[12] Suspected unlawful supply of medicines can be reported to the MHRA via its online reporting tool at gov.uk/report-problem-medicine-medical-device.

For people with high blood pressure, the risks are compounded by the absence of medical supervision. Blood pressure management requires regular monitoring, dose adjustment of any existing antihypertensive medicines and assessment of cardiovascular risk. Using an unverified injectable substance without clinical oversight could interact unpredictably with prescribed medicines or mask symptoms that require prompt medical attention. If you experience a sudden severe headache, chest pain, difficulty breathing or vision changes, call 999 immediately. For urgent but non-emergency concerns about blood pressure or medicines, contact NHS 111 or your GP.

If you are enrolled in a clinical trial and need urgent or emergency care, tell the treating clinicians that you are participating in a trial and show them your trial identification card or contact details. This allows them to contact the trial team and take your study medicine into account when making treatment decisions.

Suspected side effects from medicines can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Within a trial, adverse events should also be reported to the trial team under the study protocol. Licensed treatments for weight management and blood pressure are available through regulated NHS and private routes, and a GP is the appropriate starting point for any discussion about these options.

Frequently Asked Questions